ADINTREVIMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 09:39:41 GMT 2025` Edited by `admin` on `Wed Apr 02 09:39:41 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	054Q5D7VZI
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

ADG-20

Preferred Name

English

ADINTREVIMAB

Official Name

English

Immunoglobulin G1-lambda2, anti-[severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein, receptor binding domain (RBD)], Homo sapiens monoclonal antibody; gamma1 heavy chain Homo sapiens (1-454) [VH (Homo sapiens IGHV3-21*01

Common Name

English

ADG20

Code

English

ADINTREVIMAB [USAN]

Common Name

English

adintrevimab [INN]

Common Name

English

ADG 20 [WHO-DD]

Common Name

English

Immunoglobulin G1 [435-leucine,441-alanine], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein) (human monoclonal ADG20 ?1-chain), disulfide with human monoclonal ADG20 ?-chain, dimer

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C182620

Created by admin on Wed Apr 02 09:39:41 GMT 2025 , Edited by admin on Wed Apr 02 09:39:41 GMT 2025

PRIMARY

CAS

2516243-54-0

Created by admin on Wed Apr 02 09:39:41 GMT 2025 , Edited by admin on Wed Apr 02 09:39:41 GMT 2025

PRIMARY

USAN

KL-188

Created by admin on Wed Apr 02 09:39:41 GMT 2025 , Edited by admin on Wed Apr 02 09:39:41 GMT 2025

PRIMARY

FDA UNII

054Q5D7VZI

Created by admin on Wed Apr 02 09:39:41 GMT 2025 , Edited by admin on Wed Apr 02 09:39:41 GMT 2025

PRIMARY

SMS_ID

300000031311

Created by admin on Wed Apr 02 09:39:41 GMT 2025 , Edited by admin on Wed Apr 02 09:39:41 GMT 2025

PRIMARY

INN

12026

Created by admin on Wed Apr 02 09:39:41 GMT 2025 , Edited by admin on Wed Apr 02 09:39:41 GMT 2025

PRIMARY

From	To
1_22	1_96
2_22	2_96
2_151	2_207
2_227	4_217
2_268	2_328
1_151	1_207
2_374	2_432
3_22	3_90
3_140	3_199
4_22	4_90
4_140	4_199
1_227	3_217
1_233	2_233
1_236	2_236
1_268	1_328
1_374	1_432

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_304
N	2_304

Related Record Type Details


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->INHIBITOR

Amount:


					8R39BE7TJJ

SPIKE GLYCOPROTEIN (SARS-COV-2)

TARGET->LIGAND

Comments:

Binding studies have demonstrated that ADG20 competes with ACE-2 for binding to SARS-CoV-2 S protein thus preventing viral entry

Amount:

Related Record Type Details


					054Q5D7VZI

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID REMOVAL	[1_454] [2_454]				LYSINE	K3Z4F929H6
AMINO_ACID_SUBSTITUTION	[3_1] [4_1]	N-TERMINUS		Amount:	PIDOLIC ACID	SZB83O1W42

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL